Visual Erotica, EMG, and Sexual Psychophysiological Arousal (VESPA)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
University of British Columbia
ClinicalTrials.gov Identifier:
NCT01700361
First received: August 27, 2012
Last updated: June 3, 2013
Last verified: June 2013

August 27, 2012
June 3, 2013
October 2012
February 2013   (final data collection date for primary outcome measure)
Pelvic floor muscle sEMG activity [ Time Frame: This study involves 1 testing session approximately 20 minutes in duration ] [ Designated as safety issue: No ]
Changes in pelvic floor muscle activity in responsive to exposure to explicit sexual stimuli will be assessed using pelvic floor surface electromyography (sEMG).
Same as current
Complete list of historical versions of study NCT01700361 on ClinicalTrials.gov Archive Site
  • Sexual Arousal [ Time Frame: This study involves 1 testing session approximately 20 minutes in duration ] [ Designated as safety issue: No ]
    Self-report sexual arousal will be measured with the Sexual Arousability Inventory (SAI ; Hoon, Hoon, & Wincze, 1976)
  • Sexual Function [ Time Frame: This study involves 1 testing session approximately 20 minutes in duration ] [ Designated as safety issue: No ]
    Self-reported sexual function will be measured using the Female Sexual Function Inventory (FSFI; Rosen et al., 2000) and the Derogatis Sexual Functioning Inventory (DSFI; Derogatis & Melisaratos, 1979).
Same as current
Not Provided
Not Provided
 
Visual Erotica, EMG, and Sexual Psychophysiological Arousal (VESPA)
Visual Erotica, EMG, and Sexual Psychophysiological Arousal (VESPA)

This study will examine whether measurement of pelvic floor muscle sEMG activity is responsive to explicit sexual stimuli, and whether it correlates with self-reports of sexual arousal in healthy women. Participants' vaginal, labial and anal sEMG readings will be monitored during exposure to neutral, erotic and anxiety-provoking films. Participants will also be required to provide subjective ratings of sexual arousal before and after each film. If pelvic floor sEMG is validated as a psychophysiological measure, these findings may have important clinical and research implications by providing a greater understanding of the mechanisms involved in sexual arousal and for providing a relatively easy method of assessing sexual arousal in a clinical or research setting.

HYPOTHESES:

  1. Investigators hypothesize that, relative to the neutral films, PFM EMG activity will significantly increase in response to the erotic film as measured by the labial, anal, and vaginal EMG probes.
  2. Investigators hypothesize that, relative to the anxiety-provoking film, PFM EMG activity will significantly increase in response to the erotic film as measured by the labial, anal, and vaginal EMG probes.
  3. Investigators hypothesize that continuously measured subjective sexual arousal (via the arousometer) will correlate significantly with PFM EMG activity during the erotic film.
Observational
Time Perspective: Cross-Sectional
Not Provided
Not Provided
Non-Probability Sample

Healthy females.

Sexual Arousal
Not Provided
No treatment
This is an observational study. Women in this study are not receiving any treatments.
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
15
February 2013
February 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Must be female, between the ages of 19-45
  • Must be premenopausal
  • Must be previously sexually active
  • Must be fluent in English

Exclusion Criteria:

  • Lack of fluency in English
  • Not female between the ages of 19-45
  • Not previously sexually active
  • Any previous deliveries, either vaginal or by c-section
  • Any sexual arousal disorder
  • Any genital pain or pelvic pain disorders
  • Any bowel or bladder syndromes (e.g. interstitial cystitis, irritable bowel disease, Chron's disease)
  • Any urinary incontinence or pelvic organ prolapse
  • Undergone medically induced menopause
  • Undergone total or partial hysterectomy
  • Undergone surgery for incontinence or prolapse
  • Using estrogen suppression medication
Female
19 Years to 45 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Canada
 
NCT01700361
H12-01852
No
University of British Columbia
University of British Columbia
Not Provided
Principal Investigator: Lori A. Brotto, PhD University of British Columbia
University of British Columbia
June 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP